(ILMN is the NAS symbol on edit noticed)Speaking about Medical I found a UK based GMED and DNAP, look alike any research available from the UK, I have no URLs bookmarked:
300,000,000 or less shares out on $9 ILMN so GMED with how many out at 6 cents or so is a value What you say yes or no LOL:
siliconinvestor.com
GMED at 100 million out at 4 cents ugg EQUALIZED Gmed at what 12 cents ...this one at $9 LOL:
""
GMED - GENOMED INC
Last Price: 0.04 at 15:34 EST
Change: Up 0.001 (+2.56%)
High: 0.042 at 10:02 EST
Low: 0.039 at 15:34 EST
Open: 0.04
Previous Close: 0.039 on 3/25
Volume: 545,100
Shares Outstanding: 116,310,000 ""
www.aol.com
Illumina and Oxagen to Collaborate On Fine Mapping of SNP Loci in Genetic Linkage Regions
SAN DIEGO & ABINGDON, ENGLAND--(BW HealthWire)--March 19, 2002--
Illumina's BeadArray(TM) Technology to Enable Detailed Exploration of
Linkage Regions; Oxagen to Add Potential New Targets to Discovery
Pipeline
Illumina, Inc. (Nasdaq: ILMN) and Oxagen Limited, a private clinical genomics company, announced today that they have signed a collaborative, commercial agreement to generate detailed maps of single nucleotide polymorphism (SNP) clusters in defined chromosomal regions. Under the terms of the agreement, Oxagen will provide a collection of SNP loci within linkage regions together with samples from their extensive library of family collection material and information. Illumina will use its BeadArray technology to design functional assays for the SNPs provided and generate several million overall genotype calls from the sample set. Oxagen will retain rights to all genes and novel associations discovered as a result of the study. Further details about the agreement were not disclosed.
Jay Flatley, Illumina President & Chief Executive Officer, noted "Oxagen is taking a systematic, genome-wide approach to understanding the molecular basis of disease. Dr Nicholls and his team have built a large, proprietary collection of family samples and data, which represent a powerful resource for identifying and validating disease-causing genes. We're looking forward to our relationship with Oxagen, and we're confident that our genotyping capability will provide valuable information that paves the way for the identification of disease genes."
Dr. Trevor Nicholls, Oxagen Chief Executive Officer, commented "Oxagen has now created an exceptionally strong base of knowledge in relation to linkage regions relevant to the diseases we are studying. Illumina's BeadArray platform will give us the sample throughput and accuracy we need to extract the maximum information from our valuable samples. Equally important, Illumina's technology is driving down genotyping costs and making feasible large-scale studies like this one. We're very pleased about our collaboration with Illumina and expect that it will allow Oxagen to accelerate its development of improved therapeutic approaches and diagnostic tests."
About Illumina
Illumina ( illumina.com )( I Chucka turned all 3 links into Blue Hyperlinks in this NR ) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.
About Oxagen
Oxagen (www.oxagen.co.uk) has rapidly established itself as a leading player in the study of complex disease genetics, conducting programs in cardiovascular disease, inflammatory disease and metabolic and endocrine disorders. Oxagen aims to identify new therapeutics and diagnostics by capitalizing on insights from genetics and specializes in using large-scale family studies to understand the association of genes and genetic variations with disease. The Company believes that this approach is the most effective way to provide fundamental insights into the molecular mechanisms of disease. To this end, Oxagen is building its capabilities in functional biology to take forward these discoveries, on its own account and in partnership with major pharmaceutical companies.
Statements included in this press release that are not historical in nature may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include statements about Illumina's ability to deploy its genotyping services business for large-scale studies. Any such forward-looking statements involve risks and uncertainties and reflect Illumina's judgment as of the date of this release. Actual events or results may differ from Illumina's expectations as a result of risks and uncertainties identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission, including those discussed in "Factors Affecting Our Operating Results" and elsewhere in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000 or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release and claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
CONTACT:
Illumina, Inc.
Jay Flatley, 858/202-4501
President & Chief Executive Officer
jflatley@illumina.com
or
William Craumer, 858/202-4667
Marketing Communications Director
bcraumer@illumina.com
or
Oxagen Limited
Dr. Trevor Nicholls, +44 (0) 1235 443300
Chief Executive Officer
t.nicholls@oxagen.co.uk
or
Christine Soden, +44 (0) 1235 443300
Chief Financial Officer
c.soden@oxagen.co.uk
oxagen.co.uk
or
HCC De Facto Group
Dr. Chris Gardner, +44 (0) 20 7496 3300
c.gardner@hccdefacto.com
hccdefacto.com
Chucka ON EDIT:
ADDED: on edit:
illumina.com
home > products & services > overview
products & services
Illumina has introduced a targeted set of offerings designed for organizations conducting larger-scale research in the areas of genotyping and gene expression profiling. Leveraging core Oligator™ oligonucleotide manufacturing and BeadArray™ platform technologies, our new products and services are available for those who, like us, seek to work at production scales in a collaborative manner to understand life at the molecular level and ultimately, help usher in an era of personalized medicine.
Oligator™ Custom DNA Synthesis Services
For organizations with large-volume oligo requirements for genetic analysis applications. More information.
SNP Genotyping Services
Our BeadArray™ platform and an advanced LIMS environment provide high-throughput, accuracy and control to lower your genotyping cost per call. More information.
KEYWORD: CALIFORNIA UNITED KINGDOM INTERNATIONAL EUROPE |
